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A major challenge facing liver transplant recipients and their physicians is recurrence of hepatitis C virus infection 
following otherwise technically successful liver transplantation. Recurrent infection leads to diminished graft and 
patient survival.  Although a number or predictors of severe recurrence have been identified, no definitive strategy has 
been developed to prevent recurrence.  Generally the tempo of hepatitis C recurrence is gauged by serial liver biopsies 
with the decision to intervene with antiviral therapy based on local philosophy and expertise.  Treating hepatitis C in 
this population has a number of major challenges including diminished patient tolerance for side-effects as well as 
managing the patient’s immunesuppression. However sustained viral responses are possible with the potential to 
reduce the impact of recurrent hepatitis on the graft.  However recurrent hepatitis C virus infection will remain the most 
frequent form of recurrent disease in liver transplant programs for the foreseeable future. 
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1.  Treatment of HCV in the Liver Transplant 
Population 
Currently there are approximately 17,000 patients on 
liver transplant waiting lists throughout the U.S. with 
approximately 5,000 liver transplants performed annually 
[1,2].  Because of a critical shortage of donor livers, 10%-
12% of potential recipients die before they are 
transplanted.  About 40% of liver transplants are 
performed in patients having HCV and this number is 
expected to significantly rise during the next decade, 
especially with burgeoning rates of hepatocellular 
carcinoma [2,3].  Traditionally, cirrhotic patients were not 
considered as candidates for interferon therapy as it was 
believed that in the setting of hepatic encephalopathy, 
ascites and protein malnutrition they would not tolerate 
therapy and also that their liver disease would potentially 
decompensate with treatment.  However, improved 
response rates using the combination of pegylated 
interferon and ribavirin, greater experience in using 
hematopoietic growth factor and the need to proactively 
treat patients on the liver transplant waiting list have all 
stimulated interest in treating HCV patients with cirrhosis 
[1,4,5].  For the foreseeable future most HCV infected 
transplant candidates will be viremic at the time of 
transplant and will therefore remain at risk for recurrent 
infection.  The therapy of HCV post-OLT has evolved to 
the point where most centers base treatment decisions on 
the tempo of HCV recurrence on serial liver biopsies 
although more and larger scale studies are needed in this 
population. 
2.  Hepatitis C Post-Liver Transplantation 
In liver transplant (LT) recipients, persistence of 
hepatitis C (HCV) infection in viremic recipients almost 
always leads to graft reinfection.  In fact, serum viral titers 
may reach pre-transplant levels within the first few days 
post-operatively.  Serum levels of HCV RNA peak 1-3 
months post-transplant, reaching titers many fold higher 
than pre-transplant levels [4,6].  Furthermore, histological 
evidence of HCV recurrence occurs in over 90% of 
patients within 5 years of the transplant and has a variable 
clinical course [1,6].  Histological progression of HCV is 
accelerated after LT and can result in the fairly rapid 
development of graft failure and cirrhosis [7,8,9].  Several 
studies have shown that as many as 20% of HCV patients 
undergoing liver transplant may develop cirrhosis within 
5 years, with almost 50% developing cirrhosis within a 
decade.  Once patients develop cirrhosis from recurrent 
HCV, they are at risk for the same complications as other 
patients including variceal bleeding, ascites and 
hepatocellular carcinoma. Berenguer and colleagues 
observed rapid hepatic decompensation in LT recipients 
with graft cirrhosis due to recurrent HCV [1,4,10].   
Recent studies looking at large numbers of patients 
with adequate long-term follow-up have confirmed that 
patients with HCV undergoing liver transplantation have 
increased morbidity and mortality and have lower 5 and 
10 year survival rates when compared to patients 
undergoing liver transplantation for other etiologies of 
cirrhosis [1,8,9].  HCV is the most frequent indication for 
LT in the United States and in Europe.  By the year 2020 
the proportion of untreated HCV patients developing 
cirrhosis is expected to increase by 30%, the number of 
cirrhotic patients with HCV to increase by 100%, and the 
number of HCV cirrhotic patients developing 
hepatocellular carcinoma by 80% [2].  With the anticipated 
increase in patients requiring LT for HCV related liver 
disease, development of effective strategies to reduce graft 
failure due to HCV recurrence is essential. 
A number of reports have described accelerated 
fibrosis progression post-liver transplantation and this 
may in part be due to the age of the donor liver allograft 
[10].  The median rate of fibrosis progression is between 
0.3 and 0.6 stage per year post-transplant compared to 0.1 
to 0.2 stage per year in immunocompetent HCV patients.  
Various risk factors for poor outcomes post-LT for HCV Int. J. Med. Sci. 2006, 3  80
have been described.  Berenguer et al have shown that the 
use of liver allografts from deceased donors older than 
age 60 is associated with a more severe recurrence of HCV 
as well as a more rapid progression to cirrhosis when 
compared to LT recipients receiving allografts from 
younger donors [10].  Once patients develop cirrhosis 
post-transplant, the 1 and 3 year actuarial risks of 
decompensation are 42% and 62%, respectively, vs. less 
than 5% by 1 year and less than 20% by 5 years in 
immunocompetent patients with chronic HCV infection 
[1,4,5]. A subset of patients develop a severe cholestatic 
form of HCV that rapidly progresses to graft failure, 
similar to the fibrosing cholestatic hepatitis that originally 
described in patients with recurrent hepatitis B post-
transplant. Characteristically, there is a very high HCV 
serum RNA level, profound hyperbilirubinemia and high 
levels of alkaline phosphatase and gamma-glutamyl 
transferase, and liver biopsy reveals feathery degeneration 
predominantly in the perivenular area (Figure 1), portal 
tracts showing chronic inflammation ranging from mild-
severe with occasional lymphoid aggregates (Figure 2) 
[4,11].  Actively proliferating bile ductiles are often seen.  
Risk factors for severe recurrent HCV include advanced 
donor age, HCV genotype 1, high HCV RNA levels before 
and after transplant, early histological recurrence of HCV, 
concomitant cytomegaloviral infection, the use of T 
lymphocyte-depleting immunosuppressive agents such as 
OKT3, and treatment of presumed acute cellular rejection 
with pulse corticosteroids.  Data are conflicting as to 
whether recipient age, warm or cold ischemia times, 
gender, HLA mismatch, ethnicity or pre-transplant 
severity of illness influence the rate of recurrent HCV and 
its severity [1,4,5,12,13,14].  
Figure 1. Liver needle biopsy showing severe recurrent hepatitis C, cholestatic type.  This photomicrograph shows centrilobular 
cholestasis causing feathery degeneration of hepatocytes (long arrow).  In addition, there are foci of parenchymal necrosis including 
acidophilic bodies (short arrows). H&E stain, original magnification 200x. 
 
 
Excessive immunosuppression appears to have a deleterious effect on HCV recurrence post-liver transplant [1,15].   
High dose maintenance corticosteroid therapy for the prevention of acute cellular rejection has been associated with 
decreased patient and graft survival in HCV-infected transplant recipients.  With regard the use of cyclosporine- or 
tacrolimus-based immunosuppression, no significant differences in survival or in frequency/severity of HCV 
recurrence have been found.  The impact, if any, of azathioprine, mycophenolate mofetil and sirolimus on HCV natural 
history post-liver transplant remain unclear [1,5].  It can be extremely difficult at times to differentiate between acute 
cellular rejection and recurrent HCV histologically even for experienced liver pathologists because most patients will 
have some baseline features of hepatitis on the biopsy, as well as varying degrees of the histological features that define 
allograft rejection such as interface inflammatory changes and bile duct damage [4,16].  Thus, repeated liver biopsies 
may be required when there is an elevation in liver chemistry tests to more reliably diagnose HCV recurrence.  The 
optimal strategy in managing immunosuppression post-liver transplant in the HCV patient thus appears to be 
achieving a balance between the prevention of rejection while minimizing the potential deleterious effects of 
immunosuppression on recurrent HCV [1,4].  However, this is extremely difficult to achieve in most patients. 
In the post-liver transplant setting the differential diagnosis of elevated liver chemistry tests is broad and includes 
acute cellular or chronic ductopenic rejection, bacterial or viral (CMV most frequently) infection, drug hepatotoxicity, 
ischemia or viral hepatitis.  Approximately 20-30% of patients with recurrent HCV may have normal aminotransferases; 
it is for this reason that some centers favor protocol liver biopsies in HCV patients post-liver transplantation.   
Histologically, acute HCV recurrence is characterized by lobular infiltrates with varying degrees of hepatocyte necrosis Int. J. Med. Sci. 2006, 3  81
which may evolve over time to a chronic hepatitis with significant portal and lobular infiltrates and hepatocyte necrosis, 
as well as portal-to-portal bridging fibrosis. 
Early in the era of adult-to-adult live donor liver transplantation, preliminary reports suggested that patients 
undergoing this partial liver transplant had more severe HCV recurrence [1,4]. Although a well designed study from 
Europe did show a higher rate of graft failure in HCV recipients of live donor liver transplantation as compared to 
HCV(+) recipients of deceased donor livers, several more recent studies including one utilizing protocol liver biopsies 
and another an analysis of the UNOS database of a large number of patients, have not shown worse graft or patient 
survival in patients undergoing live donor liver transplantation [17,18].  
Several studies have shown that patients undergoing retransplantation for recurrent HCV experience significant 
morbidity and mortality. Although there is decreased patient and graft survival after retransplantation in general, it 
appears that results are even poorer for patients when the etiology of graft failure is recurrent HCV.  In a large single 
center experience Roayaie et al noted a median survival of 12.9 months in 42 patients undergoing retransplantation 
because of graft failure due to recurrent HCV; 20 of the patients died within 6 months, almost all from sepsis.  The 
presence of renal dysfunction, thrombocytopenia and coagulopathy were negative prognostic variables for survival [19].  
Whether to retransplant patients with recurrent HCV is a difficult decision because of the decreased patient and graft 
survival that occurs after retransplantation in an era in which there are frequent deaths on the liver transplant waiting 
list and a finite number of donor livers.  Whether a patient with HCV recurrence was unable to tolerate interferon 
treatment or was a virological non-responder must be considered in the decision making process when 
retransplantation becomes necessary, although data on this point is needed.  
Figure 2. Same case as above showing a portal area with a dense lymphoid aggregate typically seen in chronic hepatitis C. Arrows 




Currently, interferon-based therapies are the only 
effective treatment for HCV post-liver transplantation. 
Treatment early after liver transplant is difficult because 
of the patient's often poor performance status, their 
increased susceptibility to infection and rejection, and the 
presence of anemia and renal dysfunction that lessen the 
tolerability of interferon and ribavirin [1,4,5,20,21].  It is 
for these reasons, in addition to the fact that an 
undetectable or low viral load at the time of transplant is 
associated with less severe HCV recurrence, that pre-
transplant antiviral therapy is frequently attempted [22].  
To date, preemptive treatment to prevent HCV recurrence 
post-liver transplantation has not been shown to be highly 
effective; Chalasani et al recently demonstrated less than a 
10% sustained virological response rate in patients 
receiving 48 weeks of peginterferon alfa-2a monotherapy 
[23].  The First ILTS Expert Panel Consensus Conference 
concluded that prophylactic and preemptive antiviral 
interferon-based therapy should only be used in specific 
circumstances, such as for non-HCV patients receiving 
HCV (+) donor allografts [4].  The response rate with 
standard interferon monotherapy and standard interferon 
in combination with ribavirin to treat post-liver transplant 
HCV has generally been associated with modest response 
rates.  However, small single center trials in patients 
treating established recurrent HCV using the combination 
of pegylated interferon alpha-2b and ribavirin have 
resulted in end-of-treatment and sustained virological 
response rates ranging from 27-64% and 0-36%, 
respectively [24,25].  Treatment of recurrent HCV is 
limited by decreased patient tolerability necessitating 
frequent dose adjustment and the inability to achieve 
optimal dosing.  Approximately 30% of patients will 
discontinue therapy.  Often the only way of maintaining Int. J. Med. Sci. 2006, 3  82
the blood counts is to aggressively use hematopoietic 
growth factors.  The often poor tolerability of this 
population to any interferon and ribavirin regimen 
reflects a number of factors including concomitant 
immunosuppressive agents and associated renal 
dysfunction.  An important concern has been whether 
interferon can induce graft rejection as has been reported 
in renal transplant recipients.  Chalasani et al in their 
controlled clinical trial did not observe any increase in 
rejection rates in liver transplant recipients treated with 
pegylated alfa-2a [23].  Stravitz et al have described 
profound graft dysfunction following successful 
interferon clearance of HCV RNA with a picture 
suggestive of chronic ductopenic rejection [26].  One 
explanation may be that following clearance of HCV 
infection hepatocellular function improves and in turn 
leads to rejection. There have been increasing reports of 
pegylated interferon and ribavirin therapy possibly 
increasing the rates of both acute cellular and chronic 
ductopenic rejection [23].  Castells et al in a recent report 
described an SVR of 34% in genotype 1patients treated a 
mean of 3.4 months following OLT suggesting a role for 
therapy early in the course of HCV. Importantly a 
predictor of interferon response was an absence of 
treatment for acute rejection [28]. 
At our institution, patients with HCV undergo 
protocol liver biopsies every 6 months, and interferon and 
ribavirin are started only in the presence of progressive 
fibrosis. Firpi and colleagues from the University of 
Florida have described an important prognostic role for 
the severity of liver biopsy findings 1 year post-OLT [29].  
We utilize an escalating dose regimen of both pegylated 
interferon and ribavirin, and we aggressively utilize 
hematopoietic growth factors early in treatment to help 
stave off the need to discontinue therapy.  Although 
thrombocytopenia may persist after portal hypertension 
resolves post-transplant, it is rarely a limiting factor to 
pegylated interferon use.  We treat patients for 12 months 
and check monthly laboratory testing to exclude acute and 
chronic rejection.  
The worsening organ donor shortage has 
necessitated the use of HCV (+) allografts in recipients 
with HCV.  It appears that short-term patient and graft 
survival are similar compared with a cohort of HCV (+) 
recipients receiving HCV (-) allografts.  A HCV (+) patient 
who is HCV RNA (-) should not receive a HCV (+) 
allograft.  As it appears that the donor allograft genotype 
predominates after transplantation, our center's practice is 
to not use HCV (+) donors for patients with genotype 2 
and 3 [4,5].  It is prudent to avoid the use of HCV (+) 
livers from older donors or those having any histological 
damage. 
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